Cadrenal Therapeutics, Inc. (CVKD) 股票分析

公司概述

Cadrenal Therapeutics, Inc. operates within the healthcare sector as a late-stage biopharmaceutical company dedicated to developing therapeutics for rare cardiovascular conditions. The firm's primary strategic focus involves the development of Tecarfarin, a novel oral and reversible anticoagulant designed to prevent heart attacks, strokes, and fatalities resulting from blood clots. In terms of corporate scale, the company currently maintains a market capitalization of $12.46M, while specific annual revenue and employee count data are not publicly disclosed in the available financial records. These valuation metrics indicate that Cadrenal Therapeutics is a micro-cap entity with limited market presence, suggesting a stage of development where capital allocation is heavily directed toward research and clinical trials rather than established commercial revenue generation or large-scale operational infrastructure.

财务健康

The company reports a net income of $-13,237,362 over the trailing twelve months, accompanied by an EBITDA of $-13,454,303, which reflects significant operational burn rates typical of early-stage biotechnology firms. The absence of reported revenue figures in the TTM data suggests that current operations are entirely consumption-focused on R&D expenses rather than product sales, creating a substantial gap between nominal revenue and negative net income that highlights a cost structure dominated by development costs. Free cash flow stands at $-7,784,269, indicating that the company is converting its minimal cash reserves into cash outflows to fund its scientific pipeline and clinical progress rather than generating liquidity from operations. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, a figure that technically reflects the lack of commercial revenue and the inability to generate positive margin metrics on a sales basis. The balance sheet shows a cash position of $4.01M contrasted against zero debt, implying a conservative capital structure where the company has not yet incurred significant leverage to finance its activities. Although the debt-to-equity ratio is listed as N/A due to the absence of debt, the current ratio of 2.72 demonstrates strong short-term liquidity relative to its current liabilities, suggesting sufficient assets are available to cover obligations if revenue were to materialize. Return on Equity is recorded at -260.1% and return on assets at -116.4%, metrics that reveal the company is currently destroying shareholder and asset value as it invests capital into long-term development projects without immediate commercial return.

估值评估

Trailing twelve-month P/E ratio data is unavailable due to negative earnings, while the forward P/E is calculated at -1.27, a negative figure that implies the market is pricing the stock based on future expectations of potential profitability rather than current historical earnings performance. The price-to-book ratio stands at 4.24, indicating that the market values the company at more than four times its net book value, a premium that often reflects the potential inherent value of its intellectual property and late-stage clinical assets despite current financial losses. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also listed as negative or unavailable, specifically showing an EV/EBITDA of -0.63, which suggests that traditional valuation multiples are not applicable given the company's current lack of profitability and revenue generation. The stock has demonstrated significant volatility within the past year, trading between a 52-week high of $17.50 and a 52-week low of $4.21, highlighting a wide trading range characteristic of small-cap biotechnology stocks with high uncertainty. The beta value of 1.55 indicates that the stock's price movements are 55% more volatile than the broader market, meaning investors should expect larger swings in share price relative to market indices.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A due to the absence of positive revenue figures and negative earnings, rendering year-over-year comparisons mathematically impossible or statistically insignificant in the current reporting period. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A or 0.0%, respectively, which signifies that the firm retains all available cash to reinvest into its drug development pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for late-stage biopharmaceutical companies that prioritize advancing clinical trials over shareholder returns until product commercialization occurs. Consequently, the overall growth and income profile of Cadrenal Therapeutics is characterized by zero current yield and undefined historical growth rates, with the company's value proposition relying entirely on the potential success of Tecarfarin rather than current financial performance or income generation.